Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863113 | 0.92 | SMN1; SMN2 (0.52) | SMN1; SMN2HDAC1NAMPTHPGDHDAC3 | |
| SCHEMBL10001999 | 0.87 | SMN1; SMN2 (0.51) | SMN1; SMN2HDAC1CA2CA1HPGD | |
| SCHEMBL3641810 | 0.84 | HDAC1 (0.56) | SMN1; SMN2HDAC1CA2CA1HPGD | |
| SCHEMBL10002001 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2HDAC1CA2CA1HPGD | |
| SCHEMBL10001998 | 0.83 | CA2 (0.43) | SMN1; SMN2HDAC1CA2CA1HPGD | |
| SCHEMBL30002337 | 0.82 | NAAA (0.52) | SMN1; SMN2HDAC1CA2HPGDHDAC3 | |
| SCHEMBL27189102 | 0.82 | NAAA (0.52) | SMN1; SMN2HDAC1CA2HPGDHDAC3 | |
| SCHEMBL27189085 | 0.82 | NAAA (0.52) | SMN1; SMN2HDAC1CA2HPGDHDAC3 | |
| SCHEMBL27189079 | 0.82 | NAAA (0.52) | SMN1; SMN2HDAC1CA2HPGDHDAC3 | |
| SCHEMBL27189089 | 0.82 | NAAA (0.52) | SMN1; SMN2HDAC1CA2HPGDHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8931114-B2 | Elastomeric composites with tether-containing, conducting polymers for nanoscale diffusion control | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-01-13 | — | — | US | disclosed |
| US-20120073027-A1 | Elastomeric Composites with Tether-Containing, Conducting Polymers for Nanoscale Diffusion Control | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2012-03-29 | — | — | US | disclosed |
| US-8120893-B2 | Tether-containing conducting polymers | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100073847-A1 | TETHER-CONTAINING CONDUCTING POLYMERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120073027-A1 | Elastomeric Composites with Tether-Containing, Conducting Polymers for Nanoscale Diffusion Control | PIEZO1, TWF2, TMEM63A | SMN1; SMN2 844/4885HDAC1 2411/4885NAMPT 2028/4885 |
| US-20100073847-A1 | TETHER-CONTAINING CONDUCTING POLYMERS | SPIN4, PAH, SMC4 | SMN1; SMN2 2798/4885HDAC1 1269/4885NAMPT 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.